Medifast (MED) Equity Ratio (2010 - 2026)

Medifast (MED) has 17 years of Equity Ratio data on file, last reported at 0.78 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 4.1% year-over-year to 0.78; the trailing twelve-month figure through Mar 2026 stood at 0.78 (up 4.1% YoY), and the FY2025 full-year result was 0.8, up 8.51% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.78, down from 0.8 in the prior quarter.
• Across five years, Equity Ratio topped out at 0.8 in Q4 2025 and bottomed at 0.38 in Q2 2022.
• The 5-year median for Equity Ratio is 0.7 (2024), against an average of 0.65.
• The widest annual swing landed in 2022, when Equity Ratio slipped 28.87%; it then surged 53.13% in 2023.
• A 5-year view of Equity Ratio shows it stood at 0.49 in 2022, then jumped by 32.59% to 0.65 in 2023, then climbed by 13.71% to 0.74 in 2024, then increased by 8.51% to 0.8 in 2025, then declined by 2.23% to 0.78 in 2026.
• The last three Equity Ratio figures came in at 0.78 (Q1 2026), 0.8 (Q4 2025), and 0.8 (Q3 2025), per Business Quant data.

Peer Comparison